The GLP Dex is a structured reference for the GLP-1 drug class, organized by receptor family rather than approval date or brand name. Each family section covers the mechanism that defines that group, then profiles each drug with consistent structure: at a glance, how it works, trial data, dosing, development status, safety, and what distinguishes it from its nearest alternatives.
For the receptor biology behind the taxonomy — what GLP-1R, GIPR, and GCGR each do and why their combinations matter — see The Receptor Game.
Drug families
Single Agonists
The original GLP-1 class: semaglutide, liraglutide, exenatide, dulaglutide, and ecluglutide. One receptor, a ceiling of ~15% weight loss, and the proof of concept that incretin-based therapy works at scale.
Dual Agonists
GLP-1 plus a second receptor — six drugs targeting GIPR or GCGR alongside GLP-1R. Tirzepatide proved the ceiling could be broken. Five more are finding out what else a second receptor can do.
Triple Agonists
GLP-1R, GIPR, and GCGR simultaneously. One drug in late-stage trials — retatrutide — and one open question: how much of the efficacy is the glucagon.
Oral GLP-1
Two small-molecule non-peptide GLP-1 agonists designed to work as daily pills. Same receptor as the injectables, different molecular scaffold, different access point for patients who won't or can't inject.
Emerging Modalities
Four drugs that don't fit neatly into the other families — an amylin combination, a GLP-1/glucagon inverter, a monthly injectable, and a dual chasing cardiovascular outcomes.